PA
KNSA icon

Profund Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Profund Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,504
Closed -$215K – 1148
2024
Q2 		$215K Sell
11,504
-10,522
-48% -$197K 0.01% 944
2024
Q1 		$435K Buy
22,026
+6,138
+39% +$120K 0.02% 640
2023
Q4 		$279K Sell
15,888
-7,618
-32% -$125K 0.01% 820
2023
Q3 		$408K Buy
23,506
+1,700
+8% +$28.6K 0.02% 524
2023
Q2 		$307K Sell
21,806
-2,303
-10% -$30.8K 0.02% 707
2023
Q1 		$259K Buy
+24,109
New +$318K 0.02% 812

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Profund Advisors's KNSA Position: Q3 2024 in Review

Profund Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2024, closing a stake of 11,504 shares — an estimated $215K sold.

Profund Advisors first reported a position in KNSA in Q1 2023 and held it in 6 quarters. The position peaked at $435K in Q1 2024. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

  • Profund Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Profund Advisors sold 11,504 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $215K.
  • Profund Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Profund Advisors's Kiniksa Pharmaceuticals position peaked at $435K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on Profund Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.